Nexentix Technologies Inc
Nexentis Technologies Inc. (Nasdaq: NXTS) is redefining mitochondrial drug discovery through its wholly owned biotechnology subsidiary, MitoCareX Bio.
MitoCareX Bio
A Nexentis Technologies Inc. Company
MitoCareX Bio is a drug discovery company targeting mitochondrial SLC25 transport proteins — a historically undrugged class — to develop first-in-class therapeutics for inflammatory metabolic diseases and cancer. Powered by MITOLINE™, our proprietary computational platform, we bridge advanced in silico discovery with experimental validation to build a capital-efficient, clinically relevant pipeline.
Explore MoreGet in Touch
Whether it’s IR inquiry or whether you are a biotech or pharmaceutical company interested in licensing our technology or collaborating with us - we'd like to hear from you. Contact us at: